Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS

Model scores of the 29,894 trials active now.

Model score 23% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 15% of the time (734 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2013-06-18. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: onsetsubjectsubjects withsyndromemonths
  Phrases that lowered it: has historyevaluate theto evaluateinvestigatorparent
• Accepts healthy volunteers: No (raises risk) · Who can join
• Has a data monitoring committee: Yes (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 374 (raises risk) · Sponsor's track record
• Sponsor's past trials: 1648 (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 50% (raises risk) · Drug's FDA history
• Phase: 3 (lowers risk) · Design
• Sponsor's past termination rate: 5.0% (lowers risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports marked serious: 100% (raises risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 12 (raises risk) · Who can join
• Collaborators: 1 (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy NCT01364597 · started 2011 · scored riskier than 51% of active trials completed
• Study in Pediatric Subjects With Epilepsy NCT01494584 · started 2012 · scored riskier than 40% of active trials terminated
• Long-Term Safety Study of Retigabine Immediate Release (IR) as Adjunctive Therapy in the Treatment of Adults With Partial-Onset Seizures (POS) NCT01336621 · started 2011 · scored riskier than 90% of active trials completed
• Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome NCT03731715 · started 2019 · scored riskier than 14% of active trials completed
• Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome NCT02834793 · started 2016 · scored riskier than 26% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.